Despite a global pandemic that continued to inflict chaos and confusion on the world, resulting in fewer cancer screenings and delayed surgeries, remarkable lung cancer treatment advancements were made in 2021. From immunotherapy in the adjuvant setting to the approval of the first-in-class, highly selective inhibitor of KRAS G12C, these treatment advances have significant clinical impact in patients with lung cancer. LAY SUMMARY: There has been tremendous innovation in the treatment of nonsmall cell lung cancer. The year 2021 was marked by new approaches to adjuvant therapy and the availability of agents to target new subsets of nonsmall cell lung cancer.
Trial registration: ClinicalTrials.gov NCT02486718.
Keywords: HER2; Kirsten rat sarcoma (KRAS); adjuvant therapy; epidermal growth factor receptor (EGFR) exon 20; lung cancer.
© 2022 American Cancer Society.